Abstract 1866P
Background
The aim of this study was to compare sexual health between young breast cancer survivors and healthy young women without history of cancer, to better analyse the impact of breast cancer diagnosis and treatment on sexual health.
Methods
We conducted a cross-sectional study including all young breast cancer patients (≤40 year-old) referred for radiotherapy between 2017 and 2021. Patients were asked to fill in the Female Sexual Function Index (FSFI) in its validated Arabic translated version. A comparable cohort of young healthy women was recruited to fill in the same questionnaire. Sexual scores were calculated for both groups and statistically compared.
Results
A total of 102 young breast cancer patients (BC group) and 53 young healthy women (control group) were included in this study. Only 39.2% of breast cancer patients answered the questionnaire. Ninety-seven percent of patients underwent chemotherapy. Adjuvant endocrine therapy was prescribed for 77% of patients, of whom 97% underwent ovarian function suppression. All patients received adjuvant hypofractionated radiotherapy. Mean FSFI score was 24.01 (2.4-33) in the BC group versus 28.88 (23.8-34.4) in the control group (p=0.000). Two patients declared having unpleasurable sexual activities before their diagnosis. Sexual dysfunction (FSFI score < 26,55) was reported in 55% and 20%, respectively in the BC and control group (p=0.001). Mean desire score was 3.58 vs 4.08 (p=0.016), respectively in the BC group and the control group. Ninety-two percent of breast cancer patients suffered from hypoactive sexual desire disorder (desire score <5), versus 87% in the control group (p=0.35).
Table: 1866P
Female Sexual Function Index questionnaire scores
Domain | Breast cancer group | Control group | P value |
Desire | 3.58 | 4.08 | 0.016 |
Arousal | 3.71 | 4.56 | 0.001 |
Lubrification | 4.15 | 5.16 | 0.00 |
Orgasm | 4.23 | 4.97 | 0.007 |
Satisfaction | 4.44 | 5.49 | 0.00 |
Pain | 3.85 | 4.62 | 0.008 |
Conclusions
This study showed a significant alteration of sexual function in young breast cancer survivors when compared with a control group. Assessment and management of sexual dysfunction should become a standard practice, in order to improve quality of life and sexual health in young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05